Cook Steven L. sold $422K of OMDA

Cook Steven L. (Chief Financial Officer) sold 16,842 shares of Omada Health, Inc. (OMDA) at an average of $25.03 ($25.01–$25.03, $0.42M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Steven L.
Published Aug 12, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, share count, and the confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 framing makes it more consistent with routine selling than a fundamental change.

03

What to watch

The filing does not state tax, diversification, or personal liquidity needs; without those details, the market may over-interpret the sale size.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-12, covering sales dated 2026-08-10 to 2026-08-11

Background

The article is an SEC Form 4 insider transaction for Omada Health, Inc. (OMDA) by its CFO.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CFO Steven L. sold about $421.5K of OMDA shares via a 10b5-1 plan across two open-market trades at ~$25.01-$25.03.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The disclosure is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, regulatory, or financial guidance.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private information, but the presence of a 10b5-1 plan reduces the informational edge.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction; CFO Steven L. Cook sold shares under a 10b5-1 plan.

  • Steven L. Cook

    Chief Financial Officer who executed the open-market sales disclosed in the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.